Adjuvant Selpercatinib Prolongs EFS Among Patients with Stage II or IIIA RET Fusion-Positive NSCLC By Ogkologos - June 2, 2026 68 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LIBRETTO-432 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR seven Interesting Facts about Malignant tumors Boy Between the sheets July 20, 2023 Sacituzumab Govitecan Earns Full Approval for Triple-Negative Breast Cancer May 12, 2021 Experimental Cancer Drug Metarrestin Targets Metastatic Tumors May 29, 2018 Pump Up the Volume: “Priming Agents” May Improve Cancer Liquid Biopsies February 22, 2024 Load more HOT NEWS Her Massive Weight Loss Helped Her Feel A Lump In Her... Body Location May Influence Fate of Cells with Cancer-Causing Mutations Machine Learning-Based Model Shows Promise for Indicating Response to Immune Checkpoint... Study Says Gold Particles Injected into Tumors May Improve Cancer Patients’...
